US › Healthcare

Annovis Bio Inc (ANVS)

US · Healthcare · Biotechnology

$0.99-5.71%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.8M

EPS

$-0.40

EPS estimate

$-0.44

EPS came in at -0.40 against a street estimate of -0.44 — a beat of 9.1%.

Key statistics

Market cap

$43.5M

Forward P/E

0.0

P/B

25.18

Book value

$-0.10

EPS (TTM)

$-1.68

52-week high

$5.50

52-week low

$1.01

50-day MA

$1.46

200-day MA

$2.07

Beta

1.23

Analyst view

Analysts rate Annovis Bio Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $10.50.

Shareholding

Insiders

11.79%

Institutions

27.86%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	5.63%
Marshall Wace Asset Management Ltd	4.32%
Vanguard Capital Management, LLC	3.86%
Tudor Investment Corp Et AL	3.18%
Renaissance Technologies Corp	2.35%
Two Sigma Investments LLC	1.36%
Geode Capital Management, LLC	0.67%
BlackRock Inc	0.59%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Annovis Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.